Nicolas Leupin
Chief Tech/Sci/R&D Officer en NOVOCURE LIMITED .
Fortuna: 918 078 $ al 31/03/2024
Perfil
Nicolas Leupin is currently the Chief Medical Officer at NovoCure Ltd.
He previously held the same position at Molecular Partners AG from 2019 to 2023 and at argenx SE from 2016 to 2019.
He was also a member of the Swiss Group for Clinical Research.
Leupin holds an MBA from Jones International University and a doctorate from the University of Bern.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NOVOCURE LTD.
0.05% | 27/02/2024 | 51 124 ( 0.05% ) | 799 068 $ | 31/03/2024 |
MOLECULAR PARTNERS AG
0.08% | 31/12/2023 | 29 168 ( 0.08% ) | 119 010 $ | 31/03/2024 |
Cargos activos de Nicolas Leupin
| Empresas | Cargo | Inicio |
|---|---|---|
| NOVOCURE LIMITED | Chief Tech/Sci/R&D Officer | 04/01/2024 |
Antiguos cargos conocidos de Nicolas Leupin.
| Empresas | Cargo | Fin |
|---|---|---|
| MOLECULAR PARTNERS AG | Chief Tech/Sci/R&D Officer | 24/08/2023 |
| ARGENX SE | Chief Tech/Sci/R&D Officer | 01/07/2019 |
| Swiss Group for Clinical Research | Corporate Officer/Principal | - |
Formación de Nicolas Leupin.
| Jones International University | Masters Business Admin |
| University of Bern | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| NOVOCURE LIMITED | Health Technology |
| ARGENX SE | Health Technology |
| Empresas privadas | 1 |
|---|---|
| Swiss Group for Clinical Research |
- Bolsa de valores
- Insiders
- Nicolas Leupin
